Delaware Healthcare Fund

Objective

Delaware Healthcare Fund seeks maximum long-term capital growth through capital appreciation.

Strategy

The Fund typically invests in companies that develop, produce, or distribute products related to the healthcare or medical industries and derive a substantial portion of their sales from products and services in the healthcare industry. The Fund invests in U.S. and non-U.S. companies across all market capitalizations.

Fund information
Inception date09/28/2007
Dividends paid (if any)Annually
Capital gains paid (if any)November or December
Fund identifiers
NASDAQDLHIX
CUSIP24610E408

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted.

Total returns may reflect waivers and/or expense reimbursements by the manager and/or distributor for some or all of the periods shown. Performance would have been lower without such waivers and reimbursements.

Average annual total return

as of month-end (08/31/2016)

as of quarter-end (06/30/2016)

YTD1 year3 year5 year10 yearLifetimeInception date
NAV (view definition)-0.66%2.66%13.56%18.26%n/a16.97%09/28/2007
Russell 3000 Healthcare Index0.77%2.40%15.46%19.32%n/a10.99%
1 year3 year5 year10 yearLifetimeInception date
NAV (view definition)3.99%-6.02%14.60%15.70%n/a17.05%09/28/2007
Russell 3000 Healthcare Index6.04%-5.23%16.22%17.08%n/a10.93%

Returns for less than one year are not annualized.

Benchmark lifetime returns are as of the month end after the Fund's inception date.

Prior to January 28, 2010, the Fund had not engaged in a broad distribution effort of its shares and had been subject to limited redemption requests. The returns reflect expense limitations that were in effect during certain periods and which may have been lower than the Fund's current expenses. The returns would have been lower without expense limitations.

Index performance returns do not reflect any management fees, transaction costs, or expenses. Indices are unmanaged and one cannot invest directly in an index.

Expense ratio
Gross1.10%
Net1.10%
Quarterly total returns @ NAV
Year1st quarter2nd quarter3rd quarter4th quarterAnnual return
2016-6.41%3.99%n/an/an/a
20156.85%8.22%-12.07%9.83%11.66%
20147.41%5.36%1.17%2.47%17.32%
201317.54%8.81%9.89%7.43%50.98%
201218.59%-5.47%3.28%3.07%19.34%
20119.26%4.49%-15.90%7.33%3.06%
20107.96%-12.31%10.96%10.53%16.10%
2009-2.72%20.44%22.95%11.97%61.31%
2008-7.00%1.91%4.63%-12.08%-12.81%
2007n/an/an/a2.66%n/a

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Portfolio characteristics - as of 08/31/2016Russell 3000 Healthcare Index
Number of holdings76444
Market cap (median)$3.67 billion$0.82 billion
Market cap (weighted average)$52.29 billion$101.09 billion
Portfolio turnover (last fiscal year)46%n/a
Beta (relative to Russell 3000 Healthcare Index) (view definition)0.94n/a
Annualized standard deviation, 3 years (view definition)14.33n/a
Portfolio composition as of 08/31/2016Total may not equal 100% due to rounding.Values in excess of 100% and negative values may appear as the result of certain assets and liabilities.
Domestic equities61.8%
International equities & depositary receipts44.2%
Cash and cash equivalents-6.0%
Top 10 equity holdings as of 08/31/2016
Holdings are as of the date indicated and subject to change.
List excludes cash and cash equivalents.
Holdings based by issuer.
Holding% of portfolio
Sanofi11.9%
SINA Corp/China7.5%
Eli Lilly & Co6.4%
Bristol-Myers Squibb Co5.0%
Chugai Pharmaceutical Co Ltd4.4%
GlaxoSmithKline PLC3.9%
Quest Diagnostics Inc3.5%
Pfizer Inc3.4%
Sohu.com Inc3.2%
Amgen Inc3.2%
Total % Portfolio in Top 10 holdings52.4%

Equity sectors as of 08/31/2016

List excludes cash and cash equivalents.

SectorFundBenchmark
Blue chip medical products54.2%0.0%
Biotechnology12.2%0.0%
Healthcare services11.6%0.0%
Small/mid-cap medical products7.8%0.0%
Pharmaceutical contract research & healthcare0.5%0.0%
Distribution history - annual distributions (Institutional Class)1,2
Distributions ($ per share)
YearCapital gains3Net investment
income
20160.0000.000
20151.3430.221
20142.0720.062
20130.4200.000
20120.0000.065
20110.7550.031
20100.6510.033
20091.2800.022
20080.3400.007
20070.3010.000
20060.0000.000

1If a Fund makes a distribution from any source other than net income, it is required to provide shareholders with a notice disclosing the source of such distribution (each a "Notice"). The amounts and sources of distributions reported above and in each Notice are only estimates and are not provided for tax reporting purposes. Each Fund will send each shareholder a Form 1099 DIV for the calendar year that will provide definitive information on how to report the Fund's distributions for federal income tax purposes. The information in the table above will not be updated to reflect any subsequent recharacterization of dividends and distributions. Click here to see recent Notices pertaining to the Fund (if any).

2Information on return of capital distributions (if any) is only provided from June 1, 2014 onward.

3Includes both short- and long-term capital gains.

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

Liu-Er Chen

Liu-Er Chen, CFA

Senior Vice President, Chief Investment Officer — Emerging Markets and Healthcare

Start date on the Fund: September 2007

Years of industry experience: 20

(View bio)


Institutional Class shares are only available to certain investors. See the prospectus for more information. 

The table below describes the fees and expenses that you may pay if you buy and hold shares of the Fund.

Shareholder fees
Maximum sales charge (load) imposed on purchases as a percentage of offering pricenone
Maximum contingent deferred sales charge (load) as a percentage of original purchase price or redemption price, whichever is lowernone
Annual fund operating expenses
Management fees0.85%
Distribution and service (12b-1) feesnone
Other expenses0.25%
Total annual fund operating expenses1.10%
Fee waivers and expense reimbursementsnone
Total annual fund operating expenses after fee waivers and expense reimbursements1.10%

Institutional Class shares are only available to certain investors. See the prospectus for more information. 

View printable commentary E-mail this page

This commentary is currently not available. Please check back later.

Delaware Healthcare Fund Quarterly commentary June 30, 2016

Within the Fund

For the second quarter of 2016, Delaware Healthcare Fund (Institutional Class shares and Class A shares at net asset value) underperformed its benchmark, the Russell 3000® Healthcare Index.

Overall, healthcare stocks rose during the second quarter. After underperforming for several months, many biotechnology companies began to rebound.

The Fund’s holdings in the healthcare services sector contributed the most to relative performance due to positive stock selection. An overweight position in Quest Diagnostics was a contributor as the company has made up the market share it lost over the past two years and has resumed growth that is in line with the industry rate.

In the blue-chip medical-products sector, the Fund’s overweight in Chugai Pharmaceutical contributed to performance. Chugai Pharmaceutical is among the best franchises in Japan and is also partnered with Roche, which allows Chugai to benefit from the pipelines of both companies. Shares of Chugai rose after it announced positive earnings results. This performance was mitigated, however, by the Fund’s underweight positions in Johnson & Johnson and Pfizer. Both companies outperformed in line with other healthcare defensive stocks and have benefited from above-average top-line growth and continued margin improvements.

The Fund’s underweight position in Allergan was favorable in terms of asset allocation. Shares of the company have declined after its reverse buyout deal with Pfizer was called off. In addition, Allergan delayed divesting its generic drug unit to Teva Pharmaceutical Industries. The Fund’s position in Boston Scientific also contributed to performance. Shares of the company performed well as its turnaround effort continued.

The Fund’s positions in Sohu.com and News Corp. detracted the most from performance. Shares of Chinese Internet company Sohu.com declined due to weakness in its gaming and brand-advertising businesses. The Fund’s position in News Corp. underperformed due to continued negative momentum in its print media business. The Fund’s holdings in the biotechnology sector also detracted from performance. Shares of ImmunoGen fell after the company announced in June that it was raising cash through a convertible offering.

Outlook

For global healthcare investors, there are risks that short-term legislative and judicial action can overshadow both the positive long-term fundamentals of the sector and of specific companies. Nevertheless, we continue to see tremendous long-term opportunities in the global healthcare asset class. The baby boom generation in America is aging, implying expanding demand for healthcare products and services for decades to come. At the same time, middle classes in countries with emerging economies (notably India and China) are growing rapidly, creating big appetites for Western-style medicine. We remain positive on the sector and its growth opportunities.

Events that we continue to monitor include:

  • The Affordable Care Act (ACA). Now in their third year, the insurance exchanges created by the ACA had 8.3 million people enrolled at the end of December 2015. Although the success of the ACA is mixed and debated, it appears that the healthcare industry has responded well so far. There are still plenty of unknowns related to the ACA, and we will be monitoring developments closely, paying attention to any implications for asset prices.
  • Manufacturers of brand-name drugs were challenged as patents expired. Patent expiration means that successful brand-name drugs started losing ground to generic formulations. This has been an important shift, because brand-name drugs produced by companies like Bristol-Myers Squibb and Amgen (to name just two) have long enjoyed impressive sales records and a significant share of their respective markets. Such firms will continue to face so-called “patent cliffs.”

In light of factors like those above, we continue putting a premium on disciplined, intensive research when analyzing investment opportunities for the Fund. We favor companies that exhibit such traits as: 

  • proven competitiveness,
  • seasoned management teams, and
  • stock valuations that are discounted meaningfully from our estimates of intrinsic value.

These characteristics are part of our daily considerations as we follow our conservative, stock-by-stock approach to portfolio management.

The Russell 3000 Healthcare Index measures the performance of all healthcare holdings included in the Russell 3000 Index, which represents the 3,000 largest U.S. companies based on total market capitalization.

Russell Investment Group is the source and owner of the trademarks, service marks and copyrights related to the Russell Indexes. Russell® is a trademark of Russell Investment Group.

[17212]

The views expressed represent the Manager’s assessment of the Fund and market environment as of the date indicated, and should not be considered a recommendation to buy, hold, or sell any security, and should not be relied on as research or investment advice. Information is as of the date indicated and subject to change.

Document must be used in its entirety.

All third-party marks cited are the property of their respective owners.

Russell Investment Group is the source and owner of the trademarks, service marks, and copyrights related to the Russell Indexes. Russell® is a trademark of Russell Investment Group.

Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and other information can be found in the Fund's prospectus and its summary prospectus, which may be obtained by clicking the prospectus link located in the right-hand sidebar or calling 800 362-7500. Investors should read the prospectus and the summary prospectus carefully before investing.

Investing involves risk, including the possible loss of principal.

Narrowly focused investments may exhibit higher volatility than investments in multiple industry sectors.

Healthcare companies are subject to extensive government regulation and their profitability can be affected by restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, and malpractice or other litigation.

International investments entail risks not ordinarily associated with U.S. investments including fluctuation in currency values, differences in accounting principles, or economic or political instability in other nations.

Investing in emerging markets can be riskier than investing in established foreign markets due to increased volatility and lower trading volume.

Investments in small and/or medium-sized companies typically exhibit greater risk and higher volatility than larger, more established companies.

“Nondiversified” funds may allocate more of their net assets to investments in single securities than “diversified” funds. Resulting adverse effects may subject these funds to greater risks and volatility.

The Funds are distributed by Delaware Distributors L.P., an affiliate of Delaware Management Holdings, Inc., and Macquarie Group Limited.

Not FDIC Insured | No Bank Guarantee | May Lose Value

Fund Finder

Daily pricing (as of 09/23/2016)

Institutional ClassPriceNet change
NAV$20.26-0.11
Max offer price$20.26n/a

Total net assets (as of 08/31/2016)

$428.7 million all share classes

Overall Morningstar RatingTM

Institutional Class shares (as of 08/31/2016)
RatingNo. of funds
Overall3123
3 Yrs3123
5 Yrs3114
Morningstar categoryHealth

(View Morningstar disclosure)

Morningstar ranking (as of 08/31/2016)

YTD ranking15 / 126
1 year7 / 126
3 years63 / 123
5 years63 / 114
10 yearsn/a
Morningstar categoryHealth

(View Morningstar disclosure)

Lipper ranking (as of 08/31/2016)

YTD ranking21 / 89
1 year11 / 87
3 years41 / 80
5 years44 / 70
10 yearsn/a
Lipper classificationHealth/Biotech Funds

(View Lipper disclosure)

Benchmark, peer group

Russell 3000® Healthcare Index (view definition)

Morningstar Health Category (view definition)

Lipper Health/Biotechnology Funds Average (view definition)

Additional information